Suhuang Capsule Suppresses ER Stress to Inhibit NLRP3 Inflammasome in Cough Variant Asthma

Study Background and Research Question

Cough variant asthma (CVA) is a clinically distinct phenotype of asthma, presenting primarily with chronic cough and associated pulmonary dysfunction. Persistent inflammation and airway remodeling are central to its pathogenesis. While traditional anti-inflammatory therapies, such as corticosteroids, provide relief, there is a need for alternative interventions targeting the underlying molecular mechanisms, including endoplasmic reticulum (ER) stress and innate immune activation. The reference study by Qin et al. investigates whether the Suhuang antitussive capsule—a traditional Chinese medicine—ameliorates pulmonary dysfunction in CVA by modulating ER stress and inhibiting the NLRP3 inflammasome pathway (paper).

Key Innovation from the Reference Study

The central innovation of the study lies in elucidating the mechanistic connection between ER stress, the RIP1-RIP3-DRP1 axis, and NLRP3 inflammasome activation in the context of CVA. Suhuang’s capacity to disrupt this axis represents a novel intervention point—distinct from conventional anti-inflammatory drugs—that targets both the stress response and innate immune triggers of pulmonary dysfunction. Specifically, the research highlights how Suhuang prevents assembly of the NLRP3 inflammasome and the subsequent activation of caspase-1 and secretion of IL-1β via ER stress modulation (paper).

Methods and Experimental Design Insights

The study utilized an ovalbumin (OVA)-induced rat model of CVA to replicate the inflammatory and remodeling processes characteristic of human disease. Suhuang was administered intragastrically (i.g.) over the course of the experiment. Multiple experimental arms compared Suhuang to dexamethasone, tunicamycin (an ER stress inducer), tauroursodeoxycholic acid (ER stress inhibitor), and selective inhibitors such as Mdivi-1 (DRP1 inhibitor) and necrostatin-1 (RIP1 inhibitor). Key methods included:

• Histological assessment of pulmonary tissue for airway inflammation and remodeling.
• Bronchoalveolar lavage fluid (BALF) analysis for inflammatory cytokines.
• Western blot and immunohistochemical assays for ER stress markers (GRP78, PERK, IRE1α, ATF6) and NLRP3 inflammasome components (NLRP3, ASC, cleaved caspase-1).
• Use of pharmacological inhibitors to dissect the roles of the RIP1-RIP3-DRP1 pathway in linking ER stress to inflammasome activation.

The combination of in vivo and in vitro (primary cell) models allowed for mechanistic dissection and confirmation of pathway involvement.

Core Findings and Why They Matter

The investigators report several key outcomes:

• Suhuang significantly improves pulmonary function and reduces airway inflammation and remodeling in OVA-induced CVA rats (paper).
• ER stress is a critical upstream mediator of NLRP3 inflammasome activation in this model. Suhuang treatment reduces protein levels of ER stress markers and disrupts Ca²⁺ trafficking required for PKCε activation, providing upstream control (paper).
• NLRP3 inflammasome assembly and downstream IL-1β secretion are suppressed by Suhuang. This leads to decreased pulmonary inflammation and restoration of homeostasis.
• The RIP1-RIP3-DRP1 axis is essential for the ER stress-to-inflammasome signaling cascade. Inhibiting DRP1 with Mdivi-1 or RIP1 with necrostatin-1 recapitulates the anti-inflammatory effects of Suhuang, highlighting the role of mitochondrial dynamics in immune activation (paper).
• Pharmacological induction of ER stress by tunicamycin reverses Suhuang’s protective effects, confirming the centrality of ER stress modulation.

These findings underscore a previously underappreciated link between mitochondrial fission (via DRP1), ER stress, and innate immune activation in airway disease. The data suggest that selective DRP1 inhibitors may have therapeutic value in modulating inflammation and apoptosis in pulmonary contexts, intersecting with apoptosis assay and mitochondrial dynamics research.

Comparison with Existing Internal Articles

Recent internal articles expand on the role of DRP1 and its pharmacological inhibition. For example, the article "Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Fission" discusses how Mdivi-1 enables precise control of mitochondrial fission and apoptosis in diverse models, including neuroprotection and mitochondrial dynamics research (internal_article). This aligns with the reference study, where Mdivi-1 is used to demonstrate the necessity of DRP1-mediated mitochondrial outer membrane permeabilization for NLRP3 inflammasome activation in pulmonary inflammation. Another resource, "Mdivi-1: Next-Generation Strategies for Mitochondrial Fission Assays," provides a systems-level perspective on how DRP1 inhibition with Mdivi-1 informs advanced apoptosis assays and translational models (internal_article). The convergence of these resources supports the translational relevance of targeting mitochondrial dynamics in inflammation-associated organ dysfunction.

Protocol Parameters

• apoptosis assay | 50 μM Mdivi-1 | cell-based | Effective for inhibiting mitochondrial fission and apoptosis in mammalian cells | product_spec
• mitochondrial dynamics research | 50 μM Mdivi-1 | cell-based | Standard concentration for perturbing DRP1-dependent fission in vitro | product_spec
• neuroprotection in ischemic retina | 50 mg/kg Mdivi-1 | animal (i.p.) | Demonstrated to protect retinal ganglion cells in ischemic models | product_spec
• mitochondrial outer membrane permeabilization | 10–50 μM Mdivi-1 | cell-based | Used to block Bax/Bak-dependent cytochrome c release in apoptosis studies | workflow_recommendation
• mitochondrial fission inhibitor assay | 10–50 μM Mdivi-1 | cell-based | Range for screening DRP1-dependent fission in primary cells | workflow_recommendation

Limitations and Transferability

While the study offers compelling evidence for the role of ER stress and mitochondrial dynamics in pulmonary inflammation, several limitations should be considered:

• Rat models and primary cell systems may not fully recapitulate the human CVA pathophysiology or drug metabolism (paper).
• The complexity of traditional Chinese medicine formulations makes it difficult to attribute effects to single compounds.
• Long-term safety and efficacy of targeting the ER stress-mitochondrial axis remain to be established in clinical settings.

Nevertheless, the mechanistic insights into DRP1’s role at the intersection of ER stress, mitochondrial fragmentation, and inflammasome activation provide a valuable framework for further research in both pulmonary and broader inflammatory diseases.

Research Support Resources

To facilitate workflows investigating mitochondrial fission, apoptosis, and inflammation, researchers can use Mdivi-1 (SKU A4472), a selective, cell-permeable DRP1 inhibitor widely utilized in apoptosis assays and mitochondrial dynamics research (APExBIO). Appropriate experimental concentrations (e.g., 50 μM for cell assays or 50 mg/kg in animal studies) are supported by both literature and product specifications (product_spec). For additional insights, consult internal resources such as "Mdivi-1: Selective DRP1 Inhibitor for Mitochondrial Fission," which detail practical approaches to DRP1 inhibition in diverse experimental contexts.